The relationship between marijuana smoking and pulmonary function or respiratory complications is poorly understood; therefore, we conducted a systematic review of the impact of marijuana smoking on pulmonary function and respiratory complications.
term marijuana administration and bronchodilation (eg, increases of 0.15-0.25 L in forced expiratory volume in 1 second). No consistent association was found between long-term marijuana smoking and airflow obstruction measures. All 14 studies that assessed long-term marijuana smoking and respiratory complications noted an association with increased respiratory symptoms, including cough, phlegm, and wheeze (eg, odds ratio, 2.00; 95% confidence interval, 1.32-3.01, for the association between marijuana smoking and cough). Studies were variable in their overall quality (eg, controlling for confounders, including tobacco smoking).
Conclusions: Short-term exposure to marijuana is associated with bronchodilation. Physiologic data were inconclusive regarding an association between long-term marijuana smoking and airflow obstruction measures. Long-term marijuana smoking is associated with increased respiratory symptoms suggestive of obstructive lung disease. Med. 2007; 167: [221] [222] [223] [224] [225] [226] [227] [228] M ARIJUANA REMAINS THE most commonly used illicit drug in the United States, with 14.6 million people 12 years and older reporting current use. 1 The prevalence of marijuana abuse and dependence continues to increase and occurs in 18% of past-year marijuana users. 2 Given the persistently high prevalence of marijuana use, abuse, and dependence in the community, it is important to understand the potential adverse health outcomes that result from both short-term and long-term marijuana smoking.
Arch Intern
Marijuana and tobacco smoke share many of the same compounds. Tobacco smoking is associated with numerous adverse pulmonary clinical outcomes, affecting both pulmonary function and respiratory complications. Some of the known tobacco smoking-related adverse effects include cough, chronic bronchitis, impairment of gas exchange, and airway obstruction that leads to chronic obstructive pulmonary disease. 3, 4 The adverse impact of marijuana smoking on pulmonary function and respiratory complications has not been systematically assessed. The purpose of the current review is to determine the association between short-term marijuana smoking and airway response and the association between long-term marijuana smoking and pulmonary function or respiratory complications.
SELECTION
Retrieval of studies was performed by 2 reviewers (B.A.M. and R.M.), who evaluated titles and abstracts from the initial electronic search of potentially relevant articles. Studies were excluded if they did not report primary data, did not include human subjects, did not report results of respiratory complications or pulmonary function tests, or reported on a case series with fewer than 10 subjects. For studies that presented data on similar or duplicate cohorts, we used data that represented the last follow-up for the cohort or findings from investigations that represented assessments of unique domains or variables. Articles that could not be categorized based on review of the abstract were evaluated in manuscript form. Studies with discordant categorizations by the 2 reviewers were resolved in collaboration with a third reviewer (D.A.F., K.C., or J.M.T.) to reach consensus.
VALIDITY ASSESSMENT
Study quality was evaluated by 2 reviewers ( J.M.T. and K.C.) using an established generic instrument 5 that assessed reporting, bias or confounding, and power; a score of 12 or higher was considered good study quality. 5 We also applied exposure and disease-specific criteria to augment quality assessment using the generic instrument. For crosssectional studies, these criteria were whether data were included on prior tobacco exposure and on dose and duration of marijuana exposure and whether a standardized method to assess the pulmonary outcome of interest was used. For observational cohort studies, an additional criterion was to screen patients at baseline and exclude those with the outcome of interest. Challenge studies needed to meet the criteria listed herein and also mask patients and study personnel to marijuana use. Differences between reviewers were resolved by consensus with input from a third reviewer ( J.C. or D.A.F.). Interrater reliability was high (r = 0.79 for the generic evaluation criteria; r=0.89, Kendall b=0.85; PϽ.001 for the exposure and disease-specific criteria).
DATA SYNTHESIS
The heterogeneous nature of the studies and their outcomes precluded quantitative synthesis (ie, meta-analysis). Therefore, this review focuses on a qualitative synthesis of the data.
DATA ABSTRACTION
The initial literature search identified 965 citations. Inconsistencies regarding assessment of eligibility criteria were discussed by the whole team. Of the 965 abstracts initially reviewed, 931 were not relevant: 436 did not report primary data, 252 did not include human subjects, 173 lacked evaluation of respiratory complications or pulmonary function tests, 66 were case series of fewer than 10 patients, and 4 reported data obtained from the same patients. Ultimately, 34 unique articles were included in the review (Figure) .
The outcomes of the 34 included studies were classified into 3 non-mutually exclusive categories: airway response to experimentally administered marijuana (challenge studies), [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] changes in pulmonary function secondary to long-term marijuana smoking, [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] and respiratory complications secondary to long-term marijuana smoking. 18, 20, 22, 24, 28, [31] [32] [33] [34] [35] [36] [37] [38] [39] The studies reviewed had diverse study designs; 12 studies had a laboratory challenge study design, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] 15 were crosssectional,* 3 were observational cohort studies, 24, 26, 29 3 were case series, 20,33,39 and 1 was a case-control study. 32 
RESULTS

REVIEW OF STUDIES
CATEGORIZED BY STUDY OUTCOME
Short-term Marijuana Use and Airway Response
Twelve studies (Table 1 ) assessed the impact of short-term marijuana use on airway response. The studies used various measures to evaluate airway response: specific airway conductance (sGaw) (a measure that is inversely related to airway resistance), 6, 7, 9, 12, [14] [15] [16] forced expiratory volume in 1 second (FEV 1 ), [9] [10] [11] 14, 15 peak flow, 8 airway resistance, 17 and change in methacholine-and exerciseinduced bronchospasm. 13 Among the 7 studies that used sGaw to assess the airway response to marijuana challenge, 6 studies 6, 7, 9, 12, 15, 16 showed an increase in sGaw after marijuana challenge that ranged from 8% to 48%. Two of these studies 6, 12 showed that the increase in sGaw lasts up to 60 minutes after marijuana administration, and 1 study 12 demonstrated that peak sGaw occurred 15 minutes after smoking.
* References 18, 19, [21] [22] [23] 25, 27, 28, 30, 31, [34] [35] [36] [37] [38] . Among the 5 studies that used FEV 1 to assess airway response to marijuana challenge, 3 studies 9, 10, 15 showed an increase in FEV 1 after smoking marijuana compared with baseline, ranging from 0.15 to 0.25 L. One study 11 showed no difference in FEV 1 after marijuana challenge compared with baseline or placebo.
One study 8 used peak flow to assess marijuana effect on airway response and showed that 12 of 15 patients had an increase in peak flow immediately after marijuana inhalation, with a mean ± SD prechallenge vs postchallenge peak flow of 509.2 ± 76.1 vs 549.2 ± 66.4 L/minϫ100, respectively (PϽ.05). Another study 17 showed a mean±SD decrease in airway resistance after marijuana smoking compared with placebo (2.08± 0. 36 13 showed immediate reversal of both methacholineinduced and exercise-induced bronchospasm in patients with asthma after marijuana challenge.
One study 14 examined the impact of a more prolonged exposure to marijuana on airway response, in which subjects smoked marijuana ad libitum for 47 to 59 days in a sequestered environment. In contrast to the short-term exposure studies, this study demonstrated a decrease in sGaw compared with baseline (change of 16% ± 2%; PϽ.001) after the more prolonged exposure to marijuana, as well as a decrease in FEV 1 compared with baseline. This study also demonstrated a correlation between average daily quantity of marijuana smoked and decrease in sGaw.
Long-term Marijuana Smoking and Changes in Pulmonary Function
Fourteen studies ( Table 2) addressed the impact of long-term marijuana smoking (described as nontobacco cigarette smoking in 2 studies 18, 24 ) on abnormalities in pulmonary function, including 10 crosssectional studies, † 3 observational cohort studies, 24, 26, 29 and 1 case series.
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Of these, 9 studies [18] [19] [20] [22] [23] [24] 26, 28, 29 reported data on the effect of marijuana smoking on FEV 1 , forced vital capacity (FVC), and FEV 1 /FVC. One observational cohort study 26 reported no change in FEV 1 among marijuana smokers for a mean±SD follow-up of 4.9±2.0 years. Another observational cohort study 24 showed a 142-mL decrease in FEV 1 among patients who had previously smoked †References 18, 19, [21] [22] [23] 25, 27, 28, 30,  31. nontobacco cigarettes (PϽ.01). One case series 20 noted that long-term hashish smokers who presented with respiratory complaints had a 15% to 40% decreased FVC compared with controls. One large cross-sectional study 18 showed that male nontobacco cigarette smokers had a decrease in FEV 1 /FVC ratio compared with both nonsmokers (90% predicted vs 98.4% predicted; PϽ.05) and tobacco smokers (90% predicted vs 95.2% predicted; PϽ.05). Two other cross-sectional studies 22, 28 reported a decrease in the FEV 1 / FVC ratio among marijuana smokers when compared with nonsmokers, but after adjusting for tobacco use, 1 of these studies 22 demonstrated no difference between marijuana smokers and nonsmokers. One observational cohort study 24 reported that FEV 1 /FVC was reduced 1 year or more after nontobacco cigarette smoking compared with nonsmoking (decreased 1.9%±0.7%; PϽ.01), but no dose-response relationship was noted. Another large observational cohort study, 29 which followed up a birth cohort into adolescence, found that individuals using cannabis more than 900 times had mean FEV 1 / FVC values that were decreased 7.2% 21 reported no change in airway resistance in response to inhaled histamine in marijuana users compared with nonsmoking controls. Finally, another cross-sectional study 27 reported an association between long-term marijuana smoking and a decrease in FEV 1 to lower doses of methacholine compared with nonsmoking controls, suggesting nonspecific airway hyperresponsiveness.
Long-term Marijuana Smoking and Respiratory Complications
We reviewed 14 studies ( Table 3) that assessed the impact of longterm marijuana smoking on respiratory complications; 9 were crosssectional, 18, 22, 28, 31, [34] [35] [36] [37] [38] 3 were case series, 20,33,39 1 was a case-control study, 32 and 1 was an observational cohort. 24 All 14 studies showed an association between marijuana smoking (or nontobacco cigarette smoking) and an increased risk of various respiratory complications.
Increased cough, sputum production, and wheeze were reported in 4 of these studies. 18, 22, 24, 31 One crosssectional study 31 reported increased prevalence of chronic cough (18%-24%), sputum production (20%-26%), and wheeze (25%-37%) among marijuana and/or tobacco smokers compared with nonsmokers (PϽ.05 for all comparisons) but not between marijuana and tobacco smokers. A large cross-sectional study 18 suggested a dose response between intensity and duration of nontobacco cigarette smoking and cough. Another large cross-sectional study 22 showed that after controlling for sex, age, current asthma, and number of tobacco cigarettes smoked per day, marijuana smoking was associated with increased odds of cough (odds ratio [ 24 showed an increased odds of cough (OR, 1.73; 95% CI, 1.21-2.47), phlegm (OR, 1.53; 95% CI, 1.08-2.18), and wheeze (OR, 2.01; 95% CI, 1.50-2.70) in current nontobacco smokers compared with nonsmokers after adjusting for age, tobacco smoking, and occurrence of symptoms reported previously.
The remainder of the studies showed an association between marijuana smoking and various respiratory complications: bronchitis, 20, 22, 31, 35, 39 dyspnea, 28, 33, 35, 36 pharyngitis, 20, 35, 37 hoarse voice, 34, 35 worsening asthma symptoms, 20, 35 abnormal chest sounds, 22 worsening cystic fibrosis symptoms, 38 acute exacerbations of bronchial asthma, 32 and chest tightness.
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STUDY QUALITY
On the basis of study design, the studies reported were of variable quality using the standardized scale. 5 The mean quality score was 12.6 (range, 6-18) for the 12 challenge studies, 5.2 (range, 4-7) for the 3 case series, 10.5 (range, [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] for the 15 cross-sectional studies, 12 for the 1 case-control study, and 13 (range, [10] [11] [12] [13] [14] for the 3 observational cohort studies.
Study quality was also evaluated based on study outcome. The mean quality score for the airway response in studies of short-term marijuana use was 12.6 (range, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . For studies that evaluated changes in pulmonary function secondary to long-term marijuana smoking, the mean quality score was 11.1 (range, [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . For the studies categorized as respiratory complications secondary to long-term marijuana smoking, the mean quality score was 10.3 (range, [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] .
When also scoring publications based on disease-specific criteria, the studies that met the highest level of study quality using both scales were the 3 observational cohort studies. 24, 26, 29 Therefore, a discussion of these 3 studies in greater detail is warranted. The most recent observational cohort study 29 followed up a birth cohort of 930 participants in New Zealand to the age of 26 years. At 18, 21, and 26 years of age, marijuana and tobacco smoking were assessed with a standardized questionnaire, and pulmonary function was measured by spirometry. Confounding factors (age, tobacco smoking measured as cigarettes per day, and weight) were accounted for using a fixed-effects regression model. The authors report that during 8 years of follow-up, the dose-dependent relationship seen between cumulative marijuana smoking and decreasing FEV 1 /FVC was reduced to nonsignificant once the confounding factors were controlled for. The authors suggest that longer follow-up time is necessary for the dose-dependent relationship to persist in the context of confounding factors.
Another observational cohort study 26 followed up a convenience sample of 394 white adults for 8 years. Among the study participants, 131 were heavy and habitual smokers of marijuana, 112 smoked marijuana and tobacco, 65 smoked only tobacco, and 86 were nonsmok-(REPRINTED) ARCH INTERN MED/ VOL 167, FEB 12, 2007 WWW.ARCHINTERNMED.COM 225 ers; 255 participants had measurement of FEV 1 at least 6 times during an 8-year period. A randomeffects model, including height, intensity of marijuana use (marijuana cigarettes per day), and intensity of tobacco use (cigarettes per day) was used and failed to show a significant relationship between marijuana smoking and FEV 1 decline. Potential weaknesses of this study include lack of adjustment of duration of marijuana smoking and a low follow-up rate of 65%.
An additional observational cohort study 24 used data obtained from 3-year follow-up surveys conducted during a 6-year period in a random stratified cluster sample of households in Tucson, Ariz, between 1981 and 1988. Using a 2-stage random-effects model with height and sex as constant covariates and nontobacco cigarette smoking and tobacco cigarette smoking (and their interactions) as timedependent covariates, the authors showed that among 856 subjects for whom longitudinal pulmonary function data were available, nontobacco cigarette smokers had a significant decrease in FEV 1 /FVC ratio and previous nontobacco smokers had a decrease in FEV 1 . Of the total study population (n = 1802), current nontobacco cigarette smokers had an increase in chronic cough, phlegm, and wheeze after adjusting for age, tobacco smoking, and preexisting symptoms (from a prior assessment). The potential limitations of this study include the author's focus on subjects who smoked nontobacco cigarettes (which were assumed to contain marijuana), a relatively low number of respondents with current nontobacco cigarette smoking (range, 57-79 respondents), and different questions used to assess current nontobacco cigarette smoking in earlier surveys compared with later surveys.
COMMENT
We systematically reviewed 34 studies that assessed the impact of shortterm marijuana use on airway response and long-term marijuana smoking on pulmonary function and respiratory complications. This literature supports a bronchodilating effect soon after marijuana inhalation, although the results of 1 study suggested a reversal of this effect after more prolonged marijuana smoking. Overall, these studies fail to report a consistent association between long-term marijuana smoking and FEV 1 /FVC ratio, DL CO , or airway hyperreactivity. Finally, the literature suggests that long-term marijuana smoking is associated with an increased risk of respiratory complications, including an increase in cough, sputum production, and wheeze, persisting after adjusting for tobacco smoking. This research may inform the debate regarding the increasing use of marijuana for medical purposes accompanying recent legislative changes. 40 Our findings, however, do not directly apply to pulmonary administration of tetrahydrocannabinol via specialized delivery systems. 41 Our synthesis of the data is unique compared with other reviews in the literature. A recent review 4 reported that marijuana smoking was associated with airway inflammation, acute bronchospasm, airflow obstruction, diffusion impairment, and emphysema. Another recent review 3 noted an association between bronchodilation and increased cough, sputum, and airway inflammation with longterm marijuana smoking. Our systematic review covers a broader range of studies than previously included and also considers study quality.
The studies we reviewed were variable in quality when evaluated with a standardized assessment tool and a disease-specific assessment tool. Therefore, many methodological limitations need to be considered when interpreting the data reviewed herein. For example, many of the studies failed to adjust for important confounding factors, including tobacco, other inhaled drugs, and occupational and environmental exposures. Although some studies controlled for tobacco smoking status (ie, past, present, or never smoking), most, including the 3 observational cohort studies, did not control for dose or duration (ie, pack-years) of tobacco use, the best available measure of tobacco exposure, which is most strongly correlated with the development of obstructive lung disease. In addition, among the studies that examined the effect of long-term marijuana smoking on respiratory complications and pulmonary function, no standardized measure of marijuana dose or duration was defined. Although some studies reported marijuana cigarette-years of marijuana exposure, other studies reported only if the number of times marijuana was used by an individual was greater than a certain threshold, which varied from at least once to more than 900 times. Also, outcome measurements were not standardized. These factors pose difficulties in comparing and/or combining the results of studies. Finally, our search strategies, although extensive, may not have identified all possible studies that examined these relationships.
Despite these limitations, this review should alert primary care physicians to the potential adverse health outcomes associated with the widespread use and abuse of and dependence on marijuana. Large prospective studies should be designed that carefully account for potential confounding factors (including detailed assessments of tobacco, substance abuse, and occupational and environmental exposures) that can affect lung health. Such studies should use standard exposure and outcome criteria to accurately measure potential associations. The present findings should be considered in conjunction with a recent review 42 that showed an association between marijuana smoking and premalignant changes in the lung. On the basis of currently available information, health care professionals should consider marijuana smoking in their patients who present with respiratory complications and advise their patients regarding the potential impact of this behavior on their health. 
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